Cellosaurus logo
expasy logo

Cellosaurus NCI-H508 R2 Cetux (CVCL_A2CG)

[Text version]
Cell line name NCI-H508 R2 Cetux
Synonyms NCIH508 R2 Cetux
Accession CVCL_A2CG
Resource Identification Initiative To cite this cell line use: NCI-H508 R2 Cetux (RRID:CVCL_A2CG)
Comments Selected for resistance to: DrugBank; DB00002; Cetuximab (Erbitux).
Sequence variations
  • Mutation; HGNC; 1097; BRAF; Simple; p.Gly596Arg (c.1786G>C); ClinVar=VCV000375943; Zygosity=Heterozygous (from parent cell line).
  • Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line).
  • Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line).
Disease Cecum adenocarcinoma (NCIt: C5543)
Derived from metastatic site: Abdominal wall.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_1564 (NCI-H508)
Sex of cell Male
Age at sampling 55Y
Category Cancer cell line

PubMed=25623215; DOI=10.1158/1078-0432.CCR-14-2821
Arena S., Bellosillo B., Siravegna G., Martinez A., Canadas I., Lazzari L., Ferruz N., Russo M., Misale S., Gonzalez I., Iglesias M., Gavilan E., Corti G., Hobor S., Crisafulli G., Salido M., Sanchez J., Dalmases A., Bellmunt J., De Fabritiis G., Rovira A., Di Nicolantonio F., Albanell J., Bardelli A., Montagut C.
Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer.
Clin. Cancer Res. 21:2157-2166(2015)

Encyclopedic resources Wikidata; Q105510319
Polymorphism and mutation databases Cosmic; 2841374
Entry history
Entry creation12-Jan-2021
Last entry update20-May-2021
Version number2